Staphylococcal enterotoxins treatment

The staphylococcal enterotoxins are moderately stable proteins therefore, immunological evaluation should be possible on samples collected in either deployed or fixed medical treatment facilities. Immunoassays can detect picogram quantities of toxins in environmental samples. For comparison, 440 pg/mL was reported as the mean concentration of TSST-1 in human sera from patients with toxic shock syndrome.25 Anti-TSST-1 antibody titers are either suppressed or depleted in patients with toxic shock syndrome26,27 and the levels only recover during convalescence. In addition, most normal human serum samples contain detectable levels of antibody reacting with several different bacterial pyrogenic toxins, including... 

With the role of S. aureus as disease modifier being established, a number of therapeutic approaches may be considered (fig. 2). The potential therapeutic effect of a treatment to eradicate S. aureus in polyp disease or asthma has not been studied yet, but large-scale double-blind placebo-controlled randomized studies are currently ongoing. From atopic dermatitis, a disease sharing the modifying effects of staphylococcal superantigens on inflammation and disease severity, we can deduce therapeutic approaches. The skin of up to 100% of patients with atopic dermatitis is colonized with S. aureus, of which up to 65% have been shown to produce enterotoxins with superantigenic properties. Ten patients were treated orally with antibiotics, chlorhexidine ointment was... 

Staphylococcal entero-toxin B Enterotoxin produced by Staphylococcus aureus, may be inhaled or ingested. Onset as eariy as 3-4 hours, duration 3-4 days. Fever, chills, myalgia, cough, dyspnea, headache, nausea, vomiting symptoms usual onset 8-12 hours after exposure. Treatment supportive. Victims are not contagious, do not need isolation. Vaccine and immunotherapy effective in animals. 

---